DRAVP 2.0 expanded the antiviral peptide database to 5,688 records, a 159% increase, enhancing functional annotation and usability for antiviral research.
Absolute Event Rate: 0% vs 0%
Antiviral peptides (AVPs) offer promising therapeutic potential due to their diverse antiviral mechanisms and favorable toxicity profile. We present DRAVP 2.0, a significantly expanded and carefully curated database comprising 3,499 new entries, making a total of 5,688 records, representing a 159% increase compared to the previous version.The update incorporates sequences from peer-reviewed literature, patent records, clinical trials, and introduces stapled antiviral peptides, synthetically stabilized molecules with enhanced pharmacokinetic properties. DRAVP 2.0 features rich, multidimensional annotations, including genomic origin data (gene identifiers, chromosomal locations), structural information from UniProt and the Protein Data Bank, physicochemical properties, and experimental validation status. This comprehensive annotation framework enables detailed biological contextualization and supports cross-disciplinary studies across virology, structural biology, and genomics. The platform also offers improved usability with advanced search modes, hierarchical browsing by virus family, and an integrated BLAST tool. Regular biweekly updates and rigorous quality control ensure the database remains accurate and current. Compared to existing resources, DRAVP 2.0 provides broader coverage, enhanced functional annotation, and emphasizes experimentally validated peptides. This robust and user-friendly platform accelerates antiviral peptide discovery and therapeutic development, addressing critical needs posed by emerging and drug-resistant viral pathogens. DRAVP is available online at https://dravp.cpu-bioinfor.org/.
Nawaz et al. (Thu,) reported a other. DRAVP 2.0 expanded the antiviral peptide database to 5,688 records, a 159% increase, enhancing functional annotation and usability for antiviral research.